JMP Securities Reiterates Market Outperform on Vor Biopharma, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Silvan Tuerkcan has reiterated a Market Outperform rating for Vor Biopharma, maintaining a price target of $12.
September 06, 2024 | 2:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities has reiterated its Market Outperform rating for Vor Biopharma, maintaining a $12 price target. This suggests confidence in the company's future performance.
The reiteration of a Market Outperform rating and maintenance of a $12 price target by JMP Securities indicates a positive outlook on Vor Biopharma's stock. This could lead to increased investor confidence and potentially a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100